Vial Secures $10M Venture Debt from ATEL Ventures to Propel Pipeline

ATEL Ventures, a division of ATEL Capital Group, has announced the completion of an agreement to provide $10 million in growth capital to Vial, a clinical-stage biotech company headquartered in San Francisco. Founded in 2020, Vial focuses on advancing biologics and RNA therapeutics to address unmet medical needs. With over $100 million previously raised from investors such as General Catalyst, Buckley Ventures, and Byers Capital, Vial is progressing its innovative drug development efforts. Vial recently began its first clinical trial, exploring a monoclonal antibody targeting TL1A for inflammatory bowel disease and other conditions. This new venture debt will support Vial in moving more assets into clinical trials by 2025, amidst a growing focus on faster drug development using technology. Stephen Rea, President of ATEL Ventures, emphasized Vial's ability to streamline traditionally slow and capital-intensive processes, while CEO of Vial, Simon Burns, reiterated the importance of technological integration in their operations.